MURRYSVILLE, Pa., April 12 /PRNewswire-FirstCall/ -- Respironics, Inc. , a recognized resource in the medical device market, announced today that it intends to release its third quarter results for the period ending March 31, 2007 on Thursday, April 26, 2007. In conjunction with this release and to review the Company’s results and business outlook, Respironics will host a conference call that will be broadcast simultaneously live over the Internet.
Individuals wishing to participate on the Webcast, to be held at 8:30 a.m. EST on Thursday, April 26, 2007, can access the event at the Company’s web site at http://www.respironics.com. Please allow extra time prior to the call to visit the site and download the streaming media software required to listen to the Internet broadcast. The online archive of the broadcast will be available within 2 hours of the live call and will be available for 30 days.
Respironics is a leading developer, manufacturer and distributor of innovative products and programs that serve the global sleep and respiratory markets. Focusing on emerging market needs, the Company is committed to providing valued solutions to help improve outcomes for patients, clinicians and healthcare providers. Respironics markets its products in 131 countries and employs over 4,900 associates worldwide. Further information can be found on the Company’s Web site: http://www.respironics.com.
CAUTIONARY STATEMENT FOR PURPOSES OF THE “SAFE HARBOR” PROVISIONS OF THE PRIVATE SECURITIES REFORM ACT OF 1995.
This document contains forward-looking statements, including statements relating to, among other things, developments in the healthcare industry; the success of the Company’s marketing, sales, and promotion programs; future sales, acceptance, and quality of the Company’s products and programs; the results of clinical trials; the timing and success of new product introductions; new product development; anticipated cost savings; FDA and other regulatory requirements, enforcement actions, product recalls or related field actions; future results from acquisitions and strategic investments; growth rates in foreign markets; regulations and other factors affecting operations and sales outside the United States; foreign currency fluctuations; the effects of a major natural disaster, cyber-attack or other catastrophic event that results in the destruction or disruption of any critical business or information technology systems; customer consolidation and concentration; increasing price competition and other competitive factors in the manufacture, distribution, and sale of products; interest rate fluctuations; expiration of intellectual property rights; intellectual property and related litigation; other litigation; future levels of earnings and revenues; the number of equity awards granted to employees and changes in the Company’s stock price; and third party reimbursement; all of which are subject to change. Actual results may differ materially from those described in any forward-looking statements. Additional information on potential factors that could affect the Company’s financial results are included in the reports filed with the SEC, including the reports on Form 10-K, 10-Q and 8-K.
Respironics, Inc.
CONTACT: Dan Bevevino, Vice President & CFO, +1-724-387-5235, or General,Joe Calabrese, +1-212-827-3772, or Analyst, Julie Tu, +1-212-827-3776, allof Financial Relations Board, for Respironics, Inc.
Web site: http://www.respironics.com/
